AU5276296A - Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells - Google Patents
Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cellsInfo
- Publication number
- AU5276296A AU5276296A AU52762/96A AU5276296A AU5276296A AU 5276296 A AU5276296 A AU 5276296A AU 52762/96 A AU52762/96 A AU 52762/96A AU 5276296 A AU5276296 A AU 5276296A AU 5276296 A AU5276296 A AU 5276296A
- Authority
- AU
- Australia
- Prior art keywords
- protein
- cytomegalovirus
- introducing
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 2
- 241000701022 Cytomegalovirus Species 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 title 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 101150094182 UL84 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The human cytomegalovirus is an important disease producer in various problem groups like immuno-suppressed patients, new-born children or transplant patients. The publication concerns the use of polypeptides corresponding at least partly to the UL84 sequence as medicaments and the use of the corresponding gene in suitable transfer vectors.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19527129A DE19527129A1 (en) | 1995-07-25 | 1995-07-25 | Medicament containing at least part of the UL84 protein of cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the UL84 protein and method for introducing UL84 into target cells |
| DE19527129 | 1995-07-25 | ||
| PCT/EP1996/001428 WO1997005262A1 (en) | 1995-07-25 | 1996-04-01 | Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5276296A true AU5276296A (en) | 1997-02-26 |
Family
ID=7767728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU52762/96A Abandoned AU5276296A (en) | 1995-07-25 | 1996-04-01 | Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0840794B1 (en) |
| AT (1) | ATE317905T1 (en) |
| AU (1) | AU5276296A (en) |
| DE (2) | DE19527129A1 (en) |
| ES (1) | ES2258773T3 (en) |
| PT (1) | PT840794E (en) |
| WO (1) | WO1997005262A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4128684A1 (en) * | 1991-08-29 | 1993-03-04 | Behringwerke Ag | HCMV-SPECIFIC PEPTIDES, MEDIUM IN THIS AND THEIR USE |
-
1995
- 1995-07-25 DE DE19527129A patent/DE19527129A1/en not_active Ceased
-
1996
- 1996-04-01 WO PCT/EP1996/001428 patent/WO1997005262A1/en active IP Right Grant
- 1996-04-01 AT AT96909160T patent/ATE317905T1/en active
- 1996-04-01 DE DE59611330T patent/DE59611330D1/en not_active Expired - Lifetime
- 1996-04-01 EP EP96909160A patent/EP0840794B1/en not_active Expired - Lifetime
- 1996-04-01 AU AU52762/96A patent/AU5276296A/en not_active Abandoned
- 1996-04-01 PT PT96909160T patent/PT840794E/en unknown
- 1996-04-01 ES ES96909160T patent/ES2258773T3/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE59611330D1 (en) | 2006-04-20 |
| ATE317905T1 (en) | 2006-03-15 |
| ES2258773T3 (en) | 2006-09-01 |
| EP0840794B1 (en) | 2006-02-15 |
| EP0840794A1 (en) | 1998-05-13 |
| DE19527129A1 (en) | 1997-01-30 |
| WO1997005262A1 (en) | 1997-02-13 |
| PT840794E (en) | 2006-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7587696A (en) | Differentiation-suppressive polypeptide | |
| AU4422197A (en) | Delivery of therapeutic gene products by intestinal cell expression | |
| AU2790292A (en) | Viral recombinant vectors for expression in muscle cells | |
| LU90855I2 (en) | Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables | |
| AU3844297A (en) | Treatment of autoimmune diseases | |
| GR3022909T3 (en) | Retroviral vectors useful for gene therapy | |
| IL173399A (en) | Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medical products for producing recombinant proteins in vivo | |
| CA2164088A1 (en) | Plasmids suitable for gene therapy | |
| EP0400958A3 (en) | Live vaccines | |
| AU1170588A (en) | Methods and deoxyribonucleic acid for the preparation of tissue factor protein | |
| IL118201A0 (en) | Erythropoietin free of animal proteins processes for production and use thereof | |
| UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
| CA2066204A1 (en) | Cystic fibrosis gene | |
| AU6649996A (en) | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease | |
| NZ223551A (en) | Human interleukin-3 and related proteins, production of these using genetic engineering methods and pharmaceutical compositions | |
| AU6745287A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
| EP0744408A3 (en) | Rhesus ob protein and DNA | |
| PH27214A (en) | N-2,3-butadienyl tri and tetraaminoalkane derivatives | |
| HU895788D0 (en) | Process for producing peptides and medical products containing them | |
| HK1002284A1 (en) | Novel implant and novel vector for the treatment of acquired diseases | |
| AU5276296A (en) | Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells | |
| NO890174L (en) | RECOMBINANT INTERLEUKIN-1ALFA POLYPEPTIDES. | |
| AU6860294A (en) | New chondrocyte proteins | |
| WO2002010375A1 (en) | Human source gene leading sequence, gene vector and gene expression strategy | |
| UA5743C2 (en) | Preparation of biologically active tissue substances possessing regenerative activity and method for its production |